Positives

• Patients with Lewy body dementia in the RewinD-LB extension showed sustained slowing of cognitive decline and reduced plasma neurodegeneration biomarkers, supporting potential brain-fog applications CervoMed.
  
  
• Animal model patients showed shifted microglial activation from pro-inflammatory toward phagocytic, with improved mitochondrial function, synaptic transmission, and memory ALZForum.
  
  

Negatives

• A Long COVID patient seeking neflamapimod will find no completed PASC-specific brain fog trial yet published, with current data limited to dementia indications clinicaltrials.gov.
  
  
• Patients in earlier neflamapimod Alzheimer's trials saw the program advance only after a switch to higher TID dosing, suggesting dose-finding remains unsettled DrugBank.
  
  

Hurdles & Side Effects

• Patients can only access neflamapimod through a clinical trial, as the molecule remains investigational and not commercially available CervoMed.
  
  
• A patient hoping for Long COVID brain fog use would face the company's strategic focus on dementia with Lewy bodies, where FDA Phase 3 alignment has already been secured CervoMed.